Posters and Presentations :: SCYNEXIS, Inc. (SCYX)

<em>Aspergillus</em> isolates from patients with chronic pulmonary aspergillosis mycologically and clinically resistant to azole antifungals are sensitive to Ibrexafungerp (SCY-078)

Aspergillus isolates from patients with chronic pulmonary aspergillosis mycologically and clinically resistant to azole antifungals are sensitive to Ibrexafungerp (SCY-078)

Riina Rautemaa-Richardson, Caroline B. Moore, Katie Rawson, Lily Novak-Frazer, David Angulo, Stephen Barat, Malcolm D. Richardson
TIMM 2019
October 2019

Successful Treatment of a Patient with Retroperitoneal Abscess caused by <em>Candida krusei</em> with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI Study

Successful Treatment of a Patient with Retroperitoneal Abscess caused by Candida krusei with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI Study

George R. Thompson III, David Angulo
TIMM 2019
October 2019

<em>Candida auris</em> is Highly <em>In Vitro</em> Susceptible to Ibrexafungerp (Formerly SCY-078) in EUCAST Antifungal Susceptibility Testing

Candida auris is Highly In Vitro Susceptible to Ibrexafungerp (Formerly SCY-078) in EUCAST Antifungal Susceptibility Testing

Karin Meinike Jørgensen, Rasmus Krøger Hare, Anuradha Chowdhary and Maiken Cavling Arendrup
TIMM 2019
October 2019

Ibrexafungerp (formerly SCY-078) Demonstrates Activity Against <em>Candida auris: In Vitro, In Vivo</em> and Clinical Case Studies of Candidemia

Ibrexafungerp (formerly SCY-078) Demonstrates Activity Against Candida auris: In Vitro, In Vivo and Clinical Case Studies of Candidemia

Stephen A. Barat, Katyna Borroto-Esoda, David Angulo
TIMM 2019
October 2019

Activity of Ibrexafungerp (formerly SCY-078) Against <em>Candida auris: In Vitro, In Vivo</em> and Clinical Case Studies of Candidemia

Activity of Ibrexafungerp (formerly SCY-078) Against Candida auris: In Vitro, In Vivo and Clinical Case Studies of Candidemia

Stephen A. Barat, Katyna Borroto-Esoda, Mahmoud Ghannoum, Elizabeth Berkow, Deven Juneja, David Angulo
IDWeek 2019
October 2019

Ibrexafungerp (formerly SCY-078)

David Angulo, MD
ASM Microbe 2019
June 2019

Efficacy of Ibrexafungerp (formerly SCY-078) in a Murine Therapeutic Model of Pneumocystis Pneumonia

Stephen A. Barat, PhD
ASM Microbe 2019
June 2019

Efficacy of Ibrexafungerp (IBX, formerly SCY-078) in the Treatment of <em>Candida auris</em> Cutaneous Infection in a Guinea Pig Model

Efficacy of Ibrexafungerp (IBX, formerly SCY-078) in the Treatment of Candida auris Cutaneous Infection in a Guinea Pig Model

M. Ghannoum, L. Long, C. Hager, K. Borroto-Esoda, S. Barat, and D. Angulo
ASM Microbe 2019
June 2019

Efficacy of Ibrexafungerp (formerly SCY-078) Against <em>Pneumocystis</em> Pneumonia in a Murine Therapeutic Model

Efficacy of Ibrexafungerp (formerly SCY-078) Against Pneumocystis Pneumonia in a Murine Therapeutic Model

Stephen A. Barat, Katyna Borroto-Esoda, David A. Angulo, Alan Ashbaugh, Melanie Cushion
ASM Microbe 2019
June 2019

Preclinical Safety Evaluation of the Novel Antifungal Ibrexafungerp (formerly SCY-078) Supports Long-Term Dosing

Christina M. Carruthers, Stephen A. Barat, and David Angulo
ASM Microbe 2019
June 2019